Drug interactions between Leustatin and valganciclovir
| Results for the following 2 drugs: |
|---|
| Leustatin (cladribine) |
| valganciclovir |
Interactions between your selected drugs
cladribine ↔ valganciclovir
Applies to:Leustatin (cladribine) and valganciclovir
GENERALLY AVOID: The use of ganciclovir with other potentially myelotoxic agents may increase the risk and severity of hematologic toxicity due to additive pharmacodynamic effects. Ganciclovir alone may cause severe leucopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, bone marrow depression and aplastic anemia, and the risk may theoretically increase when coadministered with other myelotoxic therapy. Agents that may be significantly myelotoxic include antineoplastic drugs, some anticonvulsant and antirheumatic medications, albendazole, chloramphenicol, colchicine, dapsone, interferons, linezolid, pentamidine, procainamide, and zidovudine.
MANAGEMENT: Ganciclovir or its prodrug, valganciclovir, should generally not be combined with other myelotoxic drugs unless the benefits are anticipated to outweigh the potential risks. Extreme caution is advised if they are used in patients who have recently received or are receiving treatment with myelotoxic drugs, and vice versa. Reduced dosages of one or more of the drugs may be required, and patient should be monitored for the development of severe hematologic adverse effects both during and after discontinuation of therapy.
See also...
Drug Interaction Classification
The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
| Major | Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. |
| Moderate | Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. |
| Minor | Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. |
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2012 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
